Skip to main content
NCBI home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1989 Jan;64(1):77–82. doi: 10.1136/adc.64.1.77

Reversal of desferrioxamine induced auditory neurotoxicity during treatment with Ca-DTPA.

B Wonke 1, A V Hoffbrand 1, M Aldouri 1, D Wickens 1, D Flynn 1, M Stearns 1, P Warner 1
PMCID: PMC1791794  PMID: 2923478

Abstract

Auditory neurotoxicity occurred in 13 (26%) of 50 evaluable patients receiving long term desferrioxamine chelation. In five of these patients, all of whom were receiving high doses of desferrioxamine, the toxicity caused deafness. These five patients were treated with subcutaneous calcium diethylene triamine pentacetic acid (Ca-DTPA) with zinc supplements instead of desferrioxamine, and their hearing improved during periods of seven to 19 months. Their serum ion concentrations remained unchanged. We suggest that all patients receiving long term desferrioxamine should have audiometric assessments at 6-12 monthly intervals. Ca-DTPA with oral zinc supplements should be considered as alternative to desferrioxamine as an iron chelating treatment in patients with auditory neurotoxicity.

Full text

PDF
77

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Addison G. M., Beamish M. R., Hales C. N., Hodgkins M., Jacobs A., Llewellin P. An immunoradiometric assay for ferritin in the serum of normal subjects and patients with iron deficiency and iron overload. J Clin Pathol. 1972 Apr;25(4):326–329. doi: 10.1136/jcp.25.4.326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aldouri M. A., Wonke B., Hoffbrand A. V., Flynn D. M., Laulicht M., Fenton L. A., Scheuer P. J., Kibbler C. C., Allwood C. A., Brown D. Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine. J Clin Pathol. 1987 Nov;40(11):1353–1359. doi: 10.1136/jcp.40.11.1353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Constantoulakis M., Economidou J., Karagiorga M., Katsantoni A., Gyftaki E. Combined long-term treatment of hemosiderosis with desferioxamine and DTPA in homozygous beta-thalassemia. Ann N Y Acad Sci. 1974;232(0):193–200. doi: 10.1111/j.1749-6632.1974.tb20585.x. [DOI] [PubMed] [Google Scholar]
  4. Davies S. C., Marcus R. E., Hungerford J. L., Miller M. H., Arden G. B., Huehns E. R. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet. 1983 Jul 23;2(8343):181–184. doi: 10.1016/s0140-6736(83)90170-8. [DOI] [PubMed] [Google Scholar]
  5. Graziano J. H., Cerami A. Chelation therapy for the treatment of thalassemia. Semin Hematol. 1977 Jan;14(1):127–134. [PubMed] [Google Scholar]
  6. Hansen J. L., Freier E. F. The measurement of serum magnesium by atomic absorption spectrophotometry. Am J Med Technol. 1967 May-Jun;33(3):158–166. [PubMed] [Google Scholar]
  7. Hussain M. A., Green N., Flynn D. M., Hussein S., Hoffbrand A. V. Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload. Lancet. 1976 Dec 11;2(7998):1278–1280. doi: 10.1016/s0140-6736(76)92035-3. [DOI] [PubMed] [Google Scholar]
  8. Mancini G., Carbonara A. O., Heremans J. F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 1965 Sep;2(3):235–254. doi: 10.1016/0019-2791(65)90004-2. [DOI] [PubMed] [Google Scholar]
  9. Marsh M. N., Holbrook I. B., Clark C., Shaffer J. L. Tinnitus in a patient with beta-thalassaemia intermedia on long-term treatment with desferrioxamine. Postgrad Med J. 1981 Sep;57(671):582–584. doi: 10.1136/pgmj.57.671.582. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Miller K. B., Rosenwasser L. J., Bessette J. A., Beer D. J., Rocklin R. E. Rapid desensitisation for desferrioxamine anaphylactic reaction. Lancet. 1981 May 9;1(8228):1059–1059. doi: 10.1016/s0140-6736(81)92227-3. [DOI] [PubMed] [Google Scholar]
  11. Olivieri N. F., Buncic J. R., Chew E., Gallant T., Harrison R. V., Keenan N., Logan W., Mitchell D., Ricci G., Skarf B. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med. 1986 Apr 3;314(14):869–873. doi: 10.1056/NEJM198604033141402. [DOI] [PubMed] [Google Scholar]
  12. Pippard M. J., Jackson M. J., Hoffman K., Petrou M., Modell C. B. Iron chelation using subcutaneous infusions of diethylene triamine penta-acetic acid (DTPA). Scand J Haematol. 1986 May;36(5):466–472. doi: 10.1111/j.1600-0609.1986.tb02282.x. [DOI] [PubMed] [Google Scholar]
  13. Propper R. D., Cooper B., Rufo R. R., Nienhuis A. W., Anderson W. F., Bunn H. F., Rosenthal A., Nathan D. G. Continuous subcutaenous administration of deferoxamine in patients with iron overload. N Engl J Med. 1977 Aug 25;297(8):418–423. doi: 10.1056/NEJM197708252970804. [DOI] [PubMed] [Google Scholar]
  14. Rubinstein M., Dupont P., Doppee J. P., Dehon C., Ducobu J., Hainaut J. Ocular toxicity of desferrioxamine. Lancet. 1985 Apr 6;1(8432):817–818. doi: 10.1016/s0140-6736(85)91473-4. [DOI] [PubMed] [Google Scholar]
  15. Scudder P. R., Al-Timimi D., McMurray W., White A. G., Zoob B. C., Dormandy T. L. Serum copper and related variables in rheumatoid arthritis. Ann Rheum Dis. 1978 Feb;37(1):67–70. doi: 10.1136/ard.37.1.67. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES